A growing number of clinical cases have provided strong proof of concept that hematopoietic stem-cell (HSC) therapies are potential treatments for blood cancers and many other debilitating diseases that were once thought to be incurable [1]. A critical tool to enable the development of these therapies is expansion of HSCs in vitro [2]. However, supplementation …
Recently I had the opportunity to attend the Treg Summit in Boston to listen to the ground-breaking clinical and preclinical research in re-balancing the immune system in the context of autoimmunity and organ transplant via the use of polyclonal or antigen-induced T regulatory cells. Overall, this cell therapy holds immense promise as evidenced by both preclinical …
Worldwide, researchers and industry leaders are improving health outcomes for patients by utilizing the multi-functional efficacy of regulatory t cells to develop novel therapies and disease treatments. Regulatory T cells, commonly referred to as ‘T-regs’, play a critical role in maintaining order in the human immune system by regulating and suppressing excessive inflammation. Given the therapeutic …
The number and breadth of applications for induced human embryonic and pluripotent stem cells (hi-ESCs and hi-PSCs) in both research and clinical settings continue to co-evolve with our understanding of how to harness them as biological tools. In the field of cardiology, for example, it has been suggested that the ability to derive functional human …
The American Society of Gene & Cell Therapy (ASGCT) held their 22nd annual meeting in Washington D.C. last week from April 29th through May 2nd bringing together a record number of over 3,400 attendees to share and discuss the remarkable work going on to advance this field. With 23 Scientific Symposia and 1000 abstracts presented …
